Developing new options for Cystic Fibrosis lung infections

Cystic Fibrosis affects 1 in 3,500 births with approximately 70,000 patients worldwide and 31,000 in the USA alone.

Patients develop a thick sticky mucus in their lungs, which are susceptible to infection and which over time results in inflammation and lung function decline.

Respirion is developing a novel inhaled treatment for Cystic Fibrosis patients that combines a widely used antibiotic with a biofilm disrupting agent. This treatment has been shown in an initial patient study to significantly improve bacterial clearance and improve lung function.